pleasedonate

Prof Haluk Topaloğlu

Position Statement: Emerging genetic therapies for rare disorders at high cost, cannot realistically address the global burden of disease


Emerging genetic therapies for rare disorders at high cost, cannot realistically address the global burden of disease - Stakeholders must develop new pathways to ensure safe, fair and sustainable provision of such therapies A disease or disorder is defined as rare in Europe when it affects fewer than 1 in 2000 people and based on the Food and drug administration (FDA) definition from the US, when it affects less than 200,000 at any one time. Genetic factors contribute to the etiology in 80% of those with rare diseases, and other contributing factors, including infection, account for the remaining the cases....
Continue reading
  167 Hits
  0 Comments
ICNA

US FDA approves world's most expensive drug Zolgensma one-time treatment for SMA

ZOLGENSMA logo
Swiss drugmaker Novartis has received US approval for its spinal muscular atrophy gene therapy Zolgensma® (onasemnogene abeparvovec-xioiT) for the treatment of pediatric patients less than 2years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene). The one time treatment drug is priced at a record $2.125m. Novartis executives have defended the price, saying a one-time treatment is more valuable than expensive long-term treatments that cost several hundred thousand dollars a year. Zolgensma® is designed to address the genetic root cause of SMA by providing a functional copy of the human SMN gene...
Continue reading
  1014 Hits
  0 Comments
ICNA

US FDA approves Nusinersen - The first treatment for SMA


The U.S. Food and Drug Administration (FDA) approved Biogen's SPINRAZA™ (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA (nusinersen) ​ is the first and only treatment approved in the U.S. for SMA. In ENDEAR, a pivotal controlled clinical study, infantile-onset SMA patients treated with nusinersen achieved and sustained clinically meaningful improvement in motor function compared to untreated study participants. In ad...
Continue reading
  3875 Hits
  0 Comments

pleasedonate